Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 4, 1997, Pages 269-274

  Kundu, Smriti K ^a   Katzenstein, David ^a   Valentine, Fred T ^b   Spino, Cathie ^c   Efron, Bradley ^a   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cellular immune responses; Therapeutic HIV vaccination; Vital load

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ZIDOVUDINE;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030763806     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199708010-00004     Document Type: Article

References (33)

1. + T cells and HIV-1 envelope-specific cytotoxic T lymphocytes in HIV-infected asymptomatic patients. Immunology 1994;83:81-5.
2. Fauci AS. An HIV vaccine: breaking the paradigms. Proc Assoc Am Phys 1996;108:6-13.
3. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987;327:473-6.
4. Zagury D, Leonard R, Fouchad M, et al. Immunization against AIDS in humans [letter]. Nature 1987;326:249-50.
5. Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA and percentage of CD4 cells. J Infect Dis 1994;169:1256-64.
6. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients in early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-84.
7. + cytotoxic T lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992;89:11204-8.
8. 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996;173:1336-46.
9. Clark AGB, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human r-IL-2 administration. J Acquir Immune Defic Syndr 1992;5:52-9.
10. Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol 1993;31:2960-6.
11. Tsoukas CM, Raboud J, Bernard N, et al. Therapeutic vaccination: a randomized controlled study of the effect of r-gp160 on progression of immune deficiency and viral burden. Presented at the 3rd International Congress on Drug Therapy In HIV Infection, Birmingham, UK, November 3-7, 1996.
12. Goebel FD, Mannhalter JW, Eibl MM, et al. Presented at the 3rd International Congress on Drug Therapy In HIV Infection, Birmingham, UK, November 3-7, 1996.
13. Torseth JW, Berman PW, Merigan TC. Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. AIDS Res Hum Retroviruses 1988;4:23-30.
14. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1. J Virol 1994;68:5142-55.
15. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
16. Wolinsky S, Korber B, Neumann A. et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-142.
17. + cells response against human immunodeficiency virus: implications for long term survival. Proc Natl Acad Sci USA 1995;92:11135-39.
18. Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol 1995; 69:5838-42.
19. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
20. Perelson AS, Neuman AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan and viral generation time. Science 1996;271:1582-86.
21. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
22. Mellor JW, Kingsley L, Rinaldo CR, et al. Quantification of HIV-1 in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
23. Katzenstein DA, Hammer SM, Hughes M, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
24. + T lymphocytes with intermittent courses of interleukin 2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995;332:567-75.
25. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
26. Ostrowski M, Li Y, Learn G, Justement J, Stanley S, Fauci A. Examination of HIV-1 viral quasispecies after tetanus immunization. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997.
27. Chevret S, Kirstetter M, Mariotti M, Lefrere F, Frottier J, Lefrere JJ. Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:882-5.
28. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
29. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
30. Eron JJ, Ashby MA, Giordano MF, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996;348:1547-51.
31. Allan J, Conant M, Lavelle J, Mitsuyasu R, Twaddell T, Kahn J. Safety and immunogenicity of MN and IIIB rgp120/HIV-1 vaccines in HIV-1 subjects with CD4 counts >500 cells/μ1. Presented at the IXth International Conference on AIDS. Berlin, Germany, June 6-11, 1993.
32. Hamilton B, Byrn R, Giorgi J, Izu A. T cell proliferation as a measure of the immunogenicity of HIV/gp120 vaccine in seropositive subjects. Presented at the IXth International Conference on AIDS. Berlin, Germany, June 6-11, 1993.
33. Schooley RT, Spino C, Chiu S, DeGruttola V, Kuritzkes DR, for the ACTG 209 and 214 study teams. Poor immunogenicity of HIV-1 envelope vaccines with alum or MF59 adjuvant in HIV-infected individuals: results of two randomized trials. Presented at the 4th Conference on Retroviruses and Opportunistic infections. Washington, DC, January 22-26, 1997.